METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACT
A method for treating a noncancerous gynecological disorder comprising: administering to a patient an effective amount of composition to a patient, the composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.
1 . A composition for treatment of a noncancerous gynecological disorder (NCGD) selected from the group consisting of: endometriosis, an ovarian endometrioma, a deep endometriosis, dysmenorrhea, and fibroids; and wherein the composition is formulated for oral and/or systemic delivery, the composition comprising:
a cannabis extract (CE) selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a cannabidiol (CBD) isolate, and combinations thereof;
wherein the CE comprises between 20% by weight and 99.9% by weight cannabidiol (CBD) wherein the CE is between 1% and 99% by weight of the composition;
a carrier at between 1% and 99% by weight of the composition and wherein the composition is acidic with a pH between 3.5 and 6; and
one or more excipients at between 1% and 50% by weight of the composition.
2 . The composition of claim 1 further comprising cannabidiolic acid (CBDA) at a concentration of between 0.1% and 40%.
3 . The composition of claim 1 wherein the composition is formulated for systemic delivery at about 30 mg/kg weight of a patient.
4 . The composition of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.
5 . The composition of claim 1 wherein the carrier is an oil or a fat.
6 . The composition of claim 1 wherein the composition further comprises at least one additional cannabinoid at between 0.1% and 10% weight percentage of the composition wherein the at least one additional cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.